LY03017 / Luye Group - LARVOL DELTA

Luye Pharma…announces that its in-house developed innovative drug LY03017 has completed the enrollment of its first subject in a Phase II clinical trial in China for the treatment Alzheimer’s Disease-related Psychosis (ADP) (HKEXnews) - "The Phase II clinical trial in China is a randomized, double-blind, parallel-group, and placebo-controlled trial to evaluate the preliminary efficacy and safety of LY03017 in the treatment of hallucinations and delusions associated with psychosis in Alzheimer’s disease (AD). LY03017 has also been cleared to initiate clinical trials in the U.S."

Trial status • Alzheimer's Disease • Psychiatry

A Phase 1, MAD Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LY03017 (clinicaltrials.gov) - P1 | N=40 | Not yet recruiting | Sponsor: Luye Pharma Group Ltd.

New P1 trial • Alzheimer's Disease • CNS Disorders • Movement Disorders • Parkinson's Disease • Psychiatry • Schizophrenia

Effect of Food and Age on the Pharmacokinetics of LY03017 (clinicaltrials.gov) - P1 | N=26 | Not yet recruiting | Sponsor: Luye Pharma Group Ltd.

New P1 trial • Alzheimer's Disease • CNS Disorders • Movement Disorders • Parkinson's Disease • Psychiatry • Schizophrenia

A Phase 1, SAD Study to Evaluate the Safety and Tolerability of LY03017 (clinicaltrials.gov) - P1 | N=60 | Not yet recruiting | Sponsor: Luye Pharma Group Ltd.

New P1 trial • Alzheimer's Disease • CNS Disorders • Movement Disorders • Parkinson's Disease • Psychiatry • Schizophrenia